Back to Search
Start Over
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.
- Source :
- Lancet oncology, 12 (3
- Publication Year :
- 2011
-
Abstract
- Treatment with adjuvant trastuzumab for 1 year improves disease-free survival and overall survival in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. We aimed to assess disease-free survival and overall survival after a median follow-up of 4 years for patients enrolled on the Herceptin Adjuvant (HERA) trial.<br />Clinical Trial, Phase III<br />Journal Article<br />Randomized Controlled Trial<br />Research Support, Non-U.S. Gov't<br />SCOPUS: ar.j<br />info:eu-repo/semantics/published
Details
- Database :
- OAIster
- Journal :
- Lancet oncology, 12 (3
- Notes :
- 1 full-text file(s): application/pdf, English
- Publication Type :
- Electronic Resource
- Accession number :
- edsoai.ocn812600737
- Document Type :
- Electronic Resource